Work has recently been published on presenting budget impact calculations over ranges of discount or rebate scenarios for two comparators, which could be integrated into future cost of control analyses to present cost of control scenarios in which different discounts are secured for each comparator [21]
While it included activation of nuclear hormone receptors that had previously been used in effective drugs with use-limiting side effects, "if you can target those receptors to specific cell types, you might bypass some of the side effects," Habegger said
This could indicate that the GLP-1 receptor agonism successfully counters the acute hyperglycemic effects of glucagon agonism, while chronic glucagon agonism promotes body weight loss and improves in glucose tolerance [29]
The case for priority review: Retatrutide's efficacy (28.328.7% weight loss in its cleanest trials) represents a substantial improvement over the current best-approved option (tirzepatide, 22.5%) arguably a more meaningful leap than tirzepatide represented over semaglutide, which did receive expedited review consideration in some markets
Mounjaro is administered once weekly and was initially approved for the management of type 2 diabetes